Lawmakers to investigate pricing of MS drugs; Mylan will pay $465 million to resolve EpiPen allegations; the FDA approves Pfizer's new cancer drug
Prescription rates dramatically decreased following the price hikes of Valeant's Isuprel and Nitropress in 47 hospitals.
Gottlieb criticizes drugmakers for 'gaming the system' on generics; investors ignore Trump's pharma criticism; docs are more supportive of single payer
It's not often that pharmaceutical companies are held up as examples of morality or leadership to the general public.
That's why the Coalition for Healthcare Communication is focused on creating self-regulatory guidelines.
What's holding back value-based pricing deals from moving beyond the pilot phase?
The Congressional Budget Office says that Sanders' bill would save the U.S. federal government nearly $7 billion over the next decade.
Though Shkreli may soon slip from the public eye, separated from his Twitter account and prohibited from trading securities, pharma communicators must learn from these events.
Samsung Bioepis launches Remicade biosimilar; WHO encourages uses of generic version of Sovaldi; nearly 20 million people with HIV on treatment
Trump administration considers outcomes-based approach to lower drug prices; Sanofi to acquire vaccines biotech; Nestle partners with Enterome to develop microbiome-based diagnostics
The performance of generic drugs is not always guaranteed; the FDA approves a new blood thinner; Gottlieb wants rejection letters public
Insurance companies balk at expensive PCSK9 inhibitors; Publicis to focus investments on AI platform; clinical trial reveals Novartis' eye drug requires less frequent injections
Apple reportedly working to bring EMRs to iPhone; FDA to study disclosures in ads; Trump admin discussing drug price EO
The FDA asks Endo to take opioid off the market; Lilly partners with Swiss biotech; House committee advances PDUFA bill — without off-label provision
They are asking the American Medical Association to support the policy proposal.
Medicare beneficiaries struggle to pay for COPD inhalers; Novartis partners with IBM Watson Health; Mylan hasn't lowered EpiPen prices
50% of consumers say they will share their health data with tech giants; pharma CEOs expect pricing proposal from Trump administration; FDA approves generic versions of Strattera
To be sure, anything borrowing from the well-known "Keep Calm" genre should not be construed as advice. The doctor is definitely not in.
But will pharma and biotechnology firms be able to advance this year's positive momentum?
Sanofi ties price increases to growth rate; Regeneron to target 7,000 docs on new eczema drug Dupixent; NIH and biotech execs meet White House officials
Pfizer to provide Ibrance for free during NICE analysis; the FDA approves new ALS drug; people turn to Twitter to tell stories about pre-existing conditions
Louisiana may use 1910 law to discount hep-C drugs; House bill would reduce coverage for 24 million people; drugmakers pursue pay-for-performance deals
This is likely due to fewer product launches and lower price increases.
Teaching hospitals that limit detailing prescribe fewer branded drugs; new ad campaign criticizes drug pricing; Ad Age reports healthcare is fastest growing agency discipline
Some leaders have stepped up, and this serves their companies - and the industry - well.
Tesaro discloses price for new drug that differs from FDA-approved dosage; uniQure discontinues Glybera; O'Reilly leaves Fox
Groups with PhRMA ties warn against drug-pricing proposals; patients learn how to be advocates; the U.K. will not cover Opdivo for head and neck cancer
The FDA delays final rule related to off-label use; Amgen's Repatha reduces risk of death by 20%, study finds; FDA rejects AstraZeneca's hyperkalaemia drug
Marathon to sell Emflaza to PTC Therapeutics; Emma Walmsley's salary is lower than Andrew Witty's; Trump considers Medicare negotiation of drug prices
Pershing Square sells entire Valeant stake; FDA approves Novartis breast-cancer drug combo; Express Scripts asks Gilead to lower hep-C drug prices